Estradiol benzoate/hydroxyprogesterone caproate

Last updated
Estradiol benzoate /
hydroxyprogesterone caproate
Estradiol benzoate.svg
Hydroxyprogesterone caproate.svg
Estradiol benzoate (top) and
hydroxyprogesterone caproate (bottom)
Combination of
Estradiol benzoate Estrogen
Hydroxyprogesterone caproate Progestogen
Clinical data
Trade names Primosiston, others
Other namesEB/OHPC
Routes of
administration 		Intramuscular injection
ATC code
Identifiers
CAS Number
PubChem CID
PubChemSID
ChemSpider
KEGG

Estradiol benzoate/hydroxyprogesterone caproate (EB/OHPC), sold under the brand name Primosiston among others, is a combined estrogen and progestogen medication which is used to treat gynecological disorders and habitual abortion. [1] [2] [3] [4] [5] It contains estradiol benzoate (EB), an estrogen, and hydroxyprogesterone caproate (OHPC), a progestin. [1] [2] [3] [4] [5] The medication is given by injection into muscle. [1] [2] [3] [4] [5]

Contents

Medical uses

EB/OHPC is used in the treatment of gynecological disorders such as menstrual disorders (e.g., amenorrhea, dysfunctional uterine bleeding) and premenstrual syndrome, habitual abortion (threatened miscarriage), and for other indications. [1] [2] [3] [4]

Available forms

EB/OHPC is available in the form of ampoules of oil solutions containing 10 mg estradiol benzoate (EB) and 125 to 250 mg hydroxyprogesterone caproate (OHPC). [1] [2] [3] [4] [5]

History

EB/OHPC was first introduced for medical use in 1955. [6]

Society and culture

Brand names

EB/OHPC has been marketed under brand names including Dos Dias N, Lutes, Ostrolut, Primosiston (or Primosiston Inj. / Injection), Primosiston Fuerte, and Syngynon. [7] [8] [9]

Availability

EB/OHPC has been mostly discontinued and hence is mostly no longer available. [7] [8] [9] It remains marketed under the brand names Primosiston in Ecuador and Peru, Dos Dias N in Argentina, and Lutes in Japan. [7] [8] [9] It was previously marketed under the brand names Ostrolut in Austria; Primosiston (or Primosiston Inj. / Injection) (Schering) [1] [2] [4] in Argentina, Germany, Mexico, Switzerland, and Venezuela; Primosiston Fuerte in Spain; and Syngynon in Germany, but these formulations have all been discontinued and hence are no longer available in these countries. [7] [8] [9]

See also

References

  1. 1 2 3 4 5 6 Leidenberger FA (17 April 2013). Klinische Endokrinologie für Frauenärzte. Springer-Verlag. pp. 533–. ISBN   978-3-662-08110-5.
  2. 1 2 3 4 5 6 Knörr K, Beller FK, Lauritzen C (17 April 2013). Lehrbuch der Gynäkologie. Springer-Verlag. pp. 255–. ISBN   978-3-662-00942-0.
  3. 1 2 3 4 5 Kahr H (8 March 2013). Konservative Therapie der Frauenkrankheiten: Anzeigen, Grenzen und Methoden Einschliesslich der Rezeptur. Springer-Verlag. pp. 22–. ISBN   978-3-7091-5694-0.
  4. 1 2 3 4 5 6 Kern W, Auterhoff H, Neuwald F, Schmid W (9 March 2013). Hagers Handbuch der Pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Drogisten, Ärzte und Medizinalbeamte. Springer-Verlag. pp. 1163–. ISBN   978-3-642-49759-9.
  5. 1 2 3 4 Die Gestagene. Springer-Verlag. 27 November 2013. pp. 1045–. ISBN   978-3-642-99941-3.
  6. ↑ Kaiser R (2008). "Gestagen-Östrogen-Kombinationen in der Gynäkologie. Zur Geschichte, Dosierung und Anwendung eines Hormonprinzips" [Progestogen-Estrogen Combinations in Gynecology. History, Dosage, and Use of a Hormone Principle]. Geburtshilfe und Frauenheilkunde. 53 (7): 503–513. doi:10.1055/s-2007-1022924. ISSN   0016-5751. PMID   8370495. Zur kombinierten Anwendung von Gestagen en und Östrogenen stand en zunächst ölgelöstes Östradiolbenzoat und Progesteron zur Verfügung. Das erste derartige Mischpräparat kam in Deutschland 1950 auf den Mark t. Dem Wunsch nach verlän gerter Wirkungsdauer entsprach en dann Kristallmischsuspension en verschiedener Korngröße aus Östradiolmonobenzoat + Progesteron, deren Anwendung sich auf klinische Untersuchungen besch ränkte (83). Ölgelöste Depotpräparate mit Östradiolbenzoat oder -valerat + 17-hydroxyprogesteroncaproat wurden ab 1955 in die Therapie eingeführt (45.46).
  7. 1 2 3 4 "Hydroxyprogesterone". Drugs.com. Retrieved May 27, 2019.
  8. 1 2 3 4 Sweetman SC, ed. (2009). "Sex hormones and their modulators". Martindale: The Complete Drug Reference (36th ed.). London: Pharmaceutical Press. p. 2082. ISBN   978-0-85369-840-1.
  9. 1 2 3 4 "Micromedex Products: Please Login". www.micromedexsolutions.com. Retrieved May 27, 2019.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.